A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China

Prior treatment

• Patients who currently or have previously participated in any other anti-tumor clinical studies;
• Patients with NSCLC who have received any systemic anti-cancer therapy as the main treatment in the past. Cytotoxic therapy, targeted therapy (tyrosine kinase inhibitors or monoclonal antibodies) and immunotherapy included except for the use of neoadjuvant therapy;
• Patients who have received adjuvant therapy before enrollment.
• Patients with stage I-III NSCLC whose surgical resection cannot be confirmed.

Lab values

• Patients assessed by the investigator as unfit for enrollment, such as neurological disorders or metabolic disorders, physical examination or laboratory examination suspected that the patient has a possible disease, or has contraindications to the use of study drugs, or has treatment-related complications High risk etc.

• Informed consent signed;
• Newly confirmed EGFR Mutation-Positive NSCLC confirmed by histopathology except for cytology;
• Receiving or not receiving neoadjuvant treatment before surgery;
• Patients with stage I-III NSCLC undergo confirmed radical R0 resection;